Sona Nanotech's Targeted Hyperthermia Therapy Shows 38% Tumor Clearance in Colorectal Cancer Study
Key Insights
Sona Nanotech's Targeted Hyperthermia Therapy (search) combined with immunotherapy achieved 38% tumor clearance in a preclinical colorectal cancer (search) study published in the Journal of Nanobiotechnology.
The combination protocol cleared tumors in immunologically "cold" colorectal cancer (search) models within 24 days, with animals remaining disease-free for 45 days.
This marks the third cancer (search) type where Sona has demonstrated immune activation with THT, following previous success in melanoma (search) patients with an 80% clinical response rate.
Sona Nanotech Inc has reported significant progress in its cancer (search) therapy development, with new preclinical data showing that its Targeted Hyperthermia Therapy (search) (THT) combined with immunotherapy achieved complete tumor clearance in 38% of animals in a colorectal cancer (search) study. The results, published in the Journal of Nanobiotechnology, demonstrate the therapy's potential to overcome immunotherapy resistance in traditionally difficult-to-treat cancers.
Breakthrough in Immunotherapy-Resistant Cancer
The study evaluated THT in combination with PD-1 inhibitor (search) immunotherapy using an immunologically "cold" colorectal cancer (search) (CT26) model. This type of cancer (search) model is particularly significant because it represents tumors that typically resist standard immunotherapy treatments.
The combination protocol involved tumor-bearing animals receiving two consecutive THT treatments alongside a standard PD-1 inhibitor (search), followed by three additional PD-1 (search) treatments. Animals were monitored for 45 days following treatment initiation, with 38% of those receiving the combined therapy remaining alive and disease-free at the study's conclusion.
"This timely preclinical evidence of strong immune activation in colon cancer (search) using our THT/immunotherapy combination protocol reaffirms our confidence in pursuing Sona's THT to spark immunity in typically immunotherapy-resistant cancers," said Sona CEO David Regan.
Rapid Tumor Response and Biological Insights
Dr. Carman Giacomantonio, Sona's chief medical officer and the study's principal investigator, highlighted the remarkable speed of the treatment response. The 38% of treated tumors that were fully cleared achieved this outcome within 24 days of treatment initiation and remained cancer (search)-free throughout the study duration.
"This is remarkably fast by any standard of measure, and these important findings will inform the protocol for our next clinical study," Giacomantonio noted. He emphasized that this research represents the company's first publication to examine deeply the biological mechanisms behind THT treatment.
Expanding Cancer Applications
This colorectal cancer (search) study marks the third cancer (search) type in which Sona has demonstrated immune activation using THT. The company has previously shown promising results in melanoma (search), where a first-in-human study of ten late-stage patients who had failed standard-of-care immunotherapy protocols achieved an 80% clinical response rate, with 60% of treated, biopsied tumors cleared within two weeks.
The melanoma (search) study also provided evidence of an abscopal effect, where THT treatments generated clinical responses in secondary, untreated tumors. This systemic immune response suggests the therapy's potential extends beyond directly treated tumor sites.
Technology and Mechanism
Targeted Hyperthermia uses gold nanorods that absorb infrared light and re-emit it as therapeutic heat (42-48°C) within tumors. This controlled heating stimulates the immune system, shrinks tumors, inactivates cancer (search) stem cells, and increases tumor perfusion, potentially enabling drugs to reach all tumor compartments more effectively.
The technology is designed to be safe, effective, minimally invasive, and cost-competitive while serving as a valuable adjunct to drug therapy and other cancer (search) treatments.
Following the publication of these results, Sona Nanotech shares rose over 3% in Canadian trading, reflecting investor confidence in the therapy's clinical potential and the quality of the peer-reviewed research published in the highly respected Journal of Nanobiotechnology.